PCSK9 and familial hypercholesterolemia: Furthermore, in vivo single-administration of the liver-directed ABEs to inhibit PCSK9 expression is currently being evaluated in a clinical trial phase 1b (NCT05398029) for patients with heterozygous familial hypercholesterolemia, atherosclerotic cardiovascular disease, and uncontrolled hypercholesterolemia.23